Answers are grounded in this paper and cite their sources.
Patients with rare diseases deserve the same quality, safety and efficacy in medicines as other patients with more common conditions. However, for rare diseases, the cost of developing and bringing a drug to market would not normally be recovered by expected sales. In order to encourage development and research, a supportive legislative and regulatory framework known as orphan drug designation has been adopted for medicines for rare diseases in a number of countries and regions. Although similarities exist, the criteria and processes for designation are not internationally harmonised and this editorial summarises orphan drug designation in Europe, the USA and Japan.
No takes yet. Share an insight, caveat, or question.
Daniel O’Connor (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: